About us

partner with us

Improving the lives of patients by developing proprietary, innovative

In the long run, the Company aims to leverage the platform it has created to develop additional therapies. These may include expanding applications for other forms of type Our mission is to raise awareness and transform the treatment of severe aortic regurgitation.
Clinical trials completed and medical device certification obtained, enterprise value at EUR 180m. Exit strategy: second public offering on a selected stock exchange abroad e.g. Euronext, London Stock Exchange, alternatively a merger & acquisition deal

Our Partners

  • Merck

    In the long run, the Company aims to leverage the platform it has created to develop additional therapies. These may include expanding applications for other forms of type Our mission is to raise awareness and transform the treatment of severe aortic regurgitation.

  • Pfizer Eastern Europe

    In the long run, the Company aims to leverage the platform it has created to develop additional therapies. These may include expanding applications for other forms of type Our mission is to raise awareness and transform the treatment of severe aortic regurgitation.

  • Alcon

    In the long run, the Company aims to leverage the platform it has created to develop additional therapies. These may include expanding applications for other forms of type Our mission is to raise awareness and transform the treatment of severe aortic regurgitation.

  • Community Foundation

    In the long run, the Company aims to leverage the platform it has created to develop additional therapies. These may include expanding applications for other forms of type Our mission is to raise awareness and transform the treatment of severe aortic regurgitation.

become our partner

Improving the lives of patients
by developing proprietary, innovative

Prof. dr hab. n. med. Paweł Buszman, EMBA

założyciel, Prezes Zarządu, Kierownik i Główny Badacz

Współzałożyciel American Heart of Poland – największej sieci ośrodków kardiologicznych w Europie (grupa AHP została zakupiona w 2023 r. w ramach dużej międzynarodowej transakcji przez zagraniczny podmiot branżowy). Cieszący się międzynarodowym uznaniem kardiolog interwencyjny z wieloletnim doświadczeniem, wielokrotnie nagradzany przedsiębiorca, w tym EY Entrepreneur of the Year. Członek wielu międzynarodowych organizacji, m.in. Europejskiego Towarzystwa Kardiologicznego (FECC), American College of Cardiology (FACC) oraz The Society of Cardiac Angiography and Interventions (FSCAI). Kierownik i główny badacz w licznych badaniach przedklinicznych i klinicznych. Absolwent prestiżowego programu Trium Executive MBA organizowanego przez trzy uczelnie – LSE, HEC, NYSU. Autor ponad 200 publikacji.